Atea completes enrollment in Phase 3 C-FORWARD trial of bemnifosbuvir-ruzasvir hepatitis C regimen

• Atea Pharmaceuticals completed enrollment in its Phase 3 C-FORWARD trial testing bemnifosbuvir-ruzasvir for chronic hepatitis C.
• Topline C-FORWARD results will be presented in the future, expected around year-end 2026.
• The study is designed to show the regimen can match or beat a current standard-of-care option in treatment-naïve patients.
• The trial enrolled more than 880 patients across 17 countries, positioning the program for a potential broad global label if successful.
• A separate Phase 3 North American trial, C-BEYOND, remains on track to report topline results in mid-year 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atea Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606250700PRIMZONEFULLFEED9752080) on June 25, 2026, and is solely responsible for the information contained therein.